

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph under the heading “CROSS-REFERENCE TO RELATED APPLICATIONS” with the following:

This application is a continuation-in-part of U.S. patent application Ser. No. 08/571,755 (now abandoned) and a continuation of U.S. patent application Ser. No. 09/054,847 (now abandoned) which is in turn a continuation of PCT/GB96/02450 filed on Oct. 7, 1996. Priority of all of the foregoing applications is claimed under 35 U.S.C. § 120. Each of the foregoing applications is incorporated by reference herein in its entirety.

Please replace the paragraph beginning at page 27, line 14 with the following:

In particular, the binding domain may comprise one or more CDR (complementarity determining region) with an amino acid sequence shown in any of the figures. In a preferred embodiment, the binding domain comprises one or more of the CDRs, CDR1, CDR2 and/or CDR3 shown in the Figures, especially any of those shown in italics in FIG. 19 (SEQ ID NOS: 61, 63, 65, 67 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137).

Please replace the paragraph beginning at page 27, line 21 with the following:

In a preferred embodiment, the binding domain comprises a VH CDR3 sequence as shown, especially as shown in italics in FIG. 19 (SEQ ID NOS: 61, 63, 65, 67 128, 131, 134, 137). Functionally equivalent variant forms of the CDRs are encompassed by the present invention, in particular variants which differ from the CDR sequences shown by addition, deletion, substitution or insertion of one or more amino acids and which retain ability to bind the antigen and optionally one or more of the preferred characteristics for specific binding members of the present invention as disclosed herein. The specific binding member may comprise all or part of the framework regions shown flanking and between the CDRs in the

Figures, especially FIG. 19 (SEQ ID NOS: 61, 63, 65, 67), or different framework regions including modified versions of those shown.

Please replace the paragraph bridging pages 47 and 48 with the following:

FIG. 19 shows amino acid and encoding DNA sequences of regions of antibodies directed against TGF β 2 showing CDR sequences in italics: FIG 19 (i) 2A-H11 VH (also known as 6H1 VH) (SEQ ID NOS: 60, 61) with CDR1 (SEQ ID NO: 126), CDR 2 (SEQ ID NO: 127) and CDR3 (SEQ ID NO: 128) in italics; FIG.19 (ii) 6B1 VL (SEQ ID NOS: 62, 63) with CDR1 (SEQ ID NO: 129), CDR2 (SEQ ID NO: 130) and CDR3 (SEQ ID NO: 131) in italics; FIG. 19 (iii) 6A5 VL (SEQ ID NOS: 64, 65) with CDR1 (SEQ ID NO: 132), CDR2 (SEQ ID NO: 133) and CDR3 (SEQ ID NO: 134) in italics and FIG. 19 (iv) 6H1 VL (SEQ ID NOS: 66, 67) with CDR1 (SEQ ID NO: 135), CDR2 (SEQ ID NO: 136) and CDR3 (SEQ ID NO: 137) in italics.